Spruce Biosciences, Inc.
NASDAQ:SPRB · NASDAQ Capital Market
+$2.79 today
Vol 0.06M · Avg 0.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-91.7%
avg -45.6%
ROIC
-84.4%
avg -215.3%
ROA
-73.5%
avg -103.9%
Analysis
ROA is currently the strongest return metric at -73.5% versus its period average of -103.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Javier Szwarcberg | Chief Executive Officer & Director | $1.12M | — | 56 | $19,004.00 | 1.39% |
Samir Gharib | President & Chief Financial Officer | $784,043.00 | — | 44 | $497.00 | 0.04% |
Kirk Ways | Chief Medical Officer & Director | $596,833.00 | — | 73 | $0.00 | <0.01% |
Michael G. Grey | Executive Chairman | $70,000.00 | — | 73 | $1,700.00 | 0.12% |
Corwin Dale Hooks | Chief Commercial Officer | — | — | 59 | $0.00 | <0.01% |
Daven Mody | Senior Vice President of Regulatory & Quality | — | — | — | — | — |
Bruno Gagnon BPHARM | Senior Vice President of Clinical Development Operations | — | — | 57 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$4,585.16
Sells
2
$4,920.12
Net Sentiment
$334.95
Net selling
Most Active
Parkman Healthcare Partners LLC
3 transactions
Analysis
Insiders reported 1 buys worth $4,585.16 and 2 sells worth $4,920.12 over the last 12 months. That adds up to net selling of $334.95. Parkman Healthcare Partners LLC was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Equillium, Inc.
NASDAQ:EQ
$99.82M
vTv Therapeutics Inc.
NASDAQ:VTVT
$85.75M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages SPRB?
Spruce Biosciences, Inc. (SPRB) lists 7 active executives. The top listed executive is Samir Gharib, President & Chief Financial Officer.
Are SPRB insiders buying or selling?
Recent insider activity shows net buying of $10.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.